Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | DUT | P33316 | 6/20 | 0.34 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.33 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.33 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.33 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.33 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.31 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.31 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.31 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23710654 | 1.00 | POLB (0.52) | POLBHSD17B10PKMCRBNALDH1A1 | |
| SCHEMBL13471838 | 1.00 | POLB (0.52) | POLBHSD17B10PKMCRBNALDH1A1 | |
| SCHEMBL19223339 | 0.92 | POLB (0.45) | POLBHSD17B10PKMCRBNALDH1A1 | |
| SCHEMBL19223449 | 0.91 | POLB (0.44) | POLBHSD17B10PKMCRBNALDH1A1 | |
| SCHEMBL19204593 | 0.91 | POLB (0.44) | POLBHSD17B10PKMCRBNALDH1A1 | |
| SCHEMBL9909470 | 0.89 | POLB (0.43) | POLBHSD17B10PKMCRBNALDH1A1 | |
| SCHEMBL13469459 | 0.88 | POLB (0.42) | POLBHSD17B10PKMCRBNALDH1A1 | |
| SCHEMBL13468112 | 0.88 | POLB (0.42) | POLBHSD17B10PKMCRBNALDH1A1 | |
| SCHEMBL20998270 | 0.88 | POLB (0.42) | POLBHSD17B10PKMCRBNALDH1A1 | |
| SCHEMBL13468258 | 0.86 | POLB (0.41) | POLBHSD17B10PKMCRBNALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10251903-B2 | Process for making nucleoside phosphoramidate compounds | MERCK SHARP & DOHME CORP. (US) | 2019-04-09 | — | — | US | disclosed |
| US-20170246198-A1 | Process for Making Nucleoside Phosphoramidate Compounds | IDENIX PHARMACEUTICALS LLC (US) | 2017-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170246198-A1 | Process for Making Nucleoside Phosphoramidate Compounds | PNP, NUDT1, NUDT14 | POLB 183/4885HSD17B10 1474/4885PKM 888/4885 |
| US-10251903-B2 | Process for making nucleoside phosphoramidate compounds | PNP, NUDT1, NUDT14 | POLB 183/4885HSD17B10 1474/4885PKM 888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.